Alpha CD24 monoclonal antibodies - Kineta
Alternative Names: anti-CD24 mAb - Kineta; anti-CD24 monoclonal antibodies - Kineta; αCD24 mAb; αCD24 monoclonal antibodies - KinetaLatest Information Update: 23 Nov 2022
At a glance
- Originator Kineta
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD24 antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 07 Sep 2022 Early research in Solid tumours in USA (Parenteral), prior to September 2022 (Kineta pipeline, September 2022)